European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. ACN
7. BLZE
8. IBM
9. NKE
10. MU

Go back to European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) Delayed: 24.72 --0 (-0%)
Previous Close $24.72    52 Week High $37.39 
Open $24.72    52 Week Low $28.25 
Day High $24.72    P/E 14.98 
Day Low $24.72    EPS $1.65 
Volume 29,871       

Pfizer Inc. (NYSE: PFE) Delayed: 24.72 --0 (-0%)
Previous Close $24.72    52 Week High $37.39 
Open $24.72    52 Week Low $28.25 
Day High $24.72    P/E 14.98 
Day Low $24.72    EPS $1.65 
Volume 29,871